Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes

Table 1

Effects of each agent on hemodynamic parameters.

		Baseline	PBS group		Dapa 0.1 group		Dapa 1.0 group		Furo 3.0 group		Furo 30 group
			5 hours after	value	5 hours after	value	5 hours after	value	5 hours after	value	5 hours after	value
NCD-fed	SBP (mmHg)			0.868		0.497		0.028		0.063		0.000
	DBP (mmHg)			0.714		0.647		0.530		0.053		0.007
	HR (bpm)			0.747		0.719		0.498		0.001		0.027
HFD-fed	SBP (mmHg)			0.715		0.070		0.011		0.024		0.010
	DBP (mmHg)			0.975		0.683		0.379		0.003		0.000
	HR (bpm)			0.771		0.768		0.322		0.266		0.041
HFD+ MCDD-fed	SBP (mmHg)			0.986		0.249		0.010		0.042		0.001
	DBP (mmHg)			0.943		0.759		0.471		0.010		0.012
	HR (bpm)			0.644		0.758		0.664		0.045		0.007

NCD = normal chow diet; HFD = high-fat diet; MCDD = methionine-and-choline-deficient diet; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; PBS = phosphate-buffered saline; Dapa 0.1 = administration of dapagliflozin 0.1 mg/kg/day for 2 weeks; Dapa 1.0 = administration of dapagliflozin 1.0 mg/kg/day for 2 weeks; Furo 3.0 = administration of furosemide 3.0 mg/kg/day for 2 weeks; Furo 30 = administration of furosemide 30 mg/kg/day for 2 weeks. Blood pressure and heart rate immediately after intraperitoneal injection of MSA and 5 hours later are shown (). Differences between baseline (0 hours) and the 5-hour time point were analyzed using the Wilcoxon matched-pairs signed-rank test.